Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients

Table 3

Baseline characteristics of CHB patients and normal controls .

Group	Sex		Age (years)	ALT (U/l)	HBV DNA (log10IU/ml)	HBeAg (log10COI)	HBsAg (log10IU/ml)
	M	F
Normal controls	6	5	25.0 (25.0–26.0)	17.5 (10.6–35.8)	N.A.	N.A.	N.A.
Treatment-naïve patients	26	6	41.0 (35.3–48.5)	57.5 (41.5–96.0)	6.63 (5.13–7.48)	2.28 (0.00–2.88)	3.85 (3.31–4.01)
Patients with partial virological response to ETV	21	3	32.0 (28.3–37.5)	34.0 (23.3–47.0)	N.A.	1.98 (0.23–3.09)	3.85 (3.41–4.14)